fucoxanthinWhat was measured
Measured, with no finding
601 endpoints
Show what was measuredHide what was measured
body fat reduction
decreases, p = 0.001, n = 113
(3.5 +/- 1.9 kg NAFLD group, p < 0.001; 3.6 +/- 0.7 kg NLF group, p < 0.05)
PMID 19840063 · one of two readings recorded this
body fat reduction
decreases, p = 0.05, n = 38
(3.5 +/- 1.9 kg NAFLD group, p < 0.001; 3.6 +/- 0.7 kg NLF group, p < 0.05)
PMID 19840063 · one of two readings recorded this
body weight reduction
decreases, p = 0.05, n = 113
Xanthigen-600/2.4 mg (300 mg PSO + 300 mg brown seaweed extract containing 2.4 mg fucoxanthin) resulted in statistically significant reduction of body weight (5.5 +/- 1.4 kg NAFLD group and 4.9 +/- 1.2 kg NLF group, p < 0.05)
PMID 19840063 · one of two readings recorded this
body weight reduction
decreases, p = 0.05, n = 38
Xanthigen-600/2.4 mg (300 mg PSO + 300 mg brown seaweed extract containing 2.4 mg fucoxanthin) resulted in statistically significant reduction of body weight (5.5 +/- 1.4 kg NAFLD group and 4.9 +/- 1.2 kg NLF group, p < 0.05)
PMID 19840063 · one of two readings recorded this
liver fat content, liver enzymes, serum triglycerides and C-reactive protein
decreases
and liver fat content, liver enzymes (NAFLD group only), serum triglycerides and C-reactive protein
PMID 19840063 · one of two readings recorded this
resting energy expenditure
increases, n = 41
Fucoxanthin (> 2.4 mg) and Xanthigen-400/1.6 mg (200 mg PSO + 200 mg brown seaweed extract containing 1.6 mg fucoxanthin) significantly increased REE in NAFLD subjects compared to placebo
PMID 19840063 · one of two readings recorded this
resting energy expenditure
increases, n = 41
Fucoxanthin (> 2.4 mg) and Xanthigen-400/1.6 mg (200 mg PSO + 200 mg brown seaweed extract containing 1.6 mg fucoxanthin) significantly increased REE in NAFLD subjects compared to placebo
PMID 19840063 · one of two readings recorded this
waist circumference
decreases
waist circumference (NAFLD group only)
PMID 19840063 · one of two readings recorded this
cell viability and apoptosis in MCF-7 and MDA-MB-231 breast cancer cell lines
decreases
In addition, our research group have shown that 10–20 µM Fx and Fxol have inhibitory effects on cell viability and apoptosis-inducing effects on two human breast cancer cell lines, MCF-7 and MDA-MB-231.
PMID 26264004 · one of two readings recorded this
nuclear SOX9 expression in MDA-MB-231 cells
decreases
In MDA-MB-231, SOX9 was decreased at the nuclear level by Fx and Fxol.
PMID 26264004 · one of two readings recorded this
action potential plateau phase duration
decreases
67.3 ± 0.70 ms in the fucoidan-fed, 59.31 ± 0.96 ms in the fucoxanthin-fed, and 39.84 ± 1.06 ms in mice fed with both fucoidan and fucoxanthin
PMID 30669571 · one of two readings recorded this
action potential plateau phase duration
decreases
67.3 ± 0.70 ms in the fucoidan-fed, 59.31 ± 0.96 ms in the fucoxanthin-fed, and 39.84 ± 1.06 ms in mice fed with both fucoidan and fucoxanthin
PMID 30669571 · one of two readings recorded this
action potential plateau phase duration
decreases
67.3 ± 0.70 ms in the fucoidan-fed, 59.31 ± 0.96 ms in the fucoxanthin-fed, and 39.84 ± 1.06 ms in mice fed with both fucoidan and fucoxanthin
PMID 30669571 · one of two readings recorded this
action potential plateau phase duration
increases
The plateau phase was 29.28 ± 1.18 ms in the young control, 153.7 ± 6.47 ms in the aging control
PMID 30669571 · one of two readings recorded this
cardiac fibrosis (Masson's trichrome)
decreases
In the treated groups, the cardiac fibrosis was significantly reduced in the ventricle areas of the FD, FX, and FD + FX groups
PMID 30669571 · one of two readings recorded this
cardiac fibrosis (Masson's trichrome)
increases
the cardiac tissue from the SC group indicated a high proportion of fibrosis over almost the entire area
PMID 30669571 · one of two readings recorded this
CREB protein expression
increases
The CREB protein was highest in the YC group when compared to the rest of the groups
PMID 30669571 · one of two readings recorded this
Development_PIP3 signaling in cardiac myocytes pathway enrichment (GSE76374 fucoidan vs control)
modulates, p = 5.436e-13
was the most significant pathway between the fucoidan-treated group and the control group with p value = 5.436 × 10−13 and FDR = 2.549 × 10−12
PMID 30669571 · one of two readings recorded this
exhaustive swimming time
decreases, p = 0.05
There were also significant differences between the fucoidan and fucoxanthin groups and the YC group (p < 0.05)
PMID 30669571 · one of two readings recorded this
exhaustive swimming time
decreases
The aging control group had a significantly lower swimming duration (lower muscle endurance) compared to the YC group
PMID 30669571 · one of two readings recorded this
forelimb grip strength
increases
There were significant improvements after treatment with fucoidan and fucoxanthin
PMID 30669571 · one of two readings recorded this
forelimb grip strength
decreases
The SC group did significantly worse in the forelimb gripping test than the YC group
PMID 30669571 · one of two readings recorded this
GRB2 protein expression
decreases
GRB2 protein expression level was high in the YC, SC, FX, and FD groups but not in the FD + FX group
PMID 30669571 · one of two readings recorded this
GSK3β protein expression
increases
Fucoidan alone kept the expression level of this protein unchanged, whereas fucoidan in combination with HSFUCO (FD + FX) and HSFUCO (FX) alone showed increases in the level of GSK3β protein
PMID 30669571 · one of two readings recorded this
GSK3β protein expression
decreases
The GSK3β protein expression level was higher in the young control subjects than in the aging control group
PMID 30669571 · one of two readings recorded this
IRS1 protein expression
increases
The IRS1 protein level was also high in YC, FX, FD, and FX + FD but not in the SC group
PMID 30669571 · one of two readings recorded this
most significant metabolic pathways in aging
modulates
Steroid hormone biosynthesis, the citrate cycle (TCA cycle), and the glycolysis cycle were the three most significant metabolic pathways involved in the aging process
PMID 30669571 · one of two readings recorded this
QT interval on three-lead ECG (PowerLab/4SP) and ventricular action potential plateau duration by patch-clamp in two-year-old C57BL/6 mice given HSFUCO 500 mg/kg orally for 28 days, versus aging control; also forelimb grip strength, forced-swim exhaustion time, RBC reactive oxygen species
decreases
Not recorded as a finding: this platform holds no node for the endpoint
The experimental groups’ QT interval was reduced when treated with LMF and HSFUCO either alone or in combination (FD: 23.42 ± 1.1; FX: 21.39 ± 1.6; FD + FX: 14.71 ± 1.4 msec).
PMID 30669571 · one of two readings recorded this
QT interval
decreases
FD: 23.42 ± 1.1; FX: 21.39 ± 1.6; FD + FX: 14.71 ± 1.4 msec
PMID 30669571 · one of two readings recorded this
QT interval
decreases
FD: 23.42 ± 1.1; FX: 21.39 ± 1.6; FD + FX: 14.71 ± 1.4 msec
PMID 30669571 · one of two readings recorded this
QT interval
decreases
FD: 23.42 ± 1.1; FX: 21.39 ± 1.6; FD + FX: 14.71 ± 1.4 msec
PMID 30669571 · one of two readings recorded this
QT interval
increases
Prolonged QT interval was determined in the aging mice control group (SC) (25.6 ± 1.35 msec) relative to the young control group (13.62 ± 0.68 msec)
PMID 30669571 · one of two readings recorded this
red blood cell ROS activity (relative to SC = 100%)
decreases
the activity of the YC, SC, FD, FX, and FD + FX groups were 23.39%, 100%, 65.58%, 63.57% and 40.34%, respectively
PMID 30669571 · one of two readings recorded this
red blood cell ROS activity (relative to SC = 100%)
decreases
the activity of the YC, SC, FD, FX, and FD + FX groups were 23.39%, 100%, 65.58%, 63.57% and 40.34%, respectively
PMID 30669571 · one of two readings recorded this
red blood cell ROS activity (relative to SC = 100%)
decreases
the activity of the YC, SC, FD, FX, and FD + FX groups were 23.39%, 100%, 65.58%, 63.57% and 40.34%, respectively
PMID 30669571 · one of two readings recorded this
red blood cell ROS activity (relative to SC = 100%)
increases
the activity of the YC, SC, FD, FX, and FD + FX groups were 23.39%, 100%, 65.58%, 63.57% and 40.34%, respectively
PMID 30669571 · one of two readings recorded this
red blood cell ROS activity (relative to SC = 100%)
decreases
the activity of the YC, SC, FD, FX, and FD + FX groups were 23.39%, 100%, 65.58%, 63.57% and 40.34%, respectively
PMID 30669571 · one of two readings recorded this
SOS1 protein expression
increases
Under treatment by HSFUCO, the expression level of SOS1 was increased compared to that of the aging group
PMID 30669571 · one of two readings recorded this
SOS1 protein expression
no effect
the combined effect of fucoidan and HSFUCO showed a comparable level of SOS1 protein expression to that of the aging group
PMID 30669571 · one of two readings recorded this
urinary metabolite profile (PLS-DA, 57 metabolites)
modulates
The young control and aging control subjects could be distinguished from the aging subjects treated with fucoidan (FD); however, the FD mice did not come close to the YC group
PMID 30669571 · one of two readings recorded this
fasting blood glucose
increases
PTE300-supplemented mice, which had fasting blood glucose levels significantly higher than control and PTE100-supplemented mice
PMID 30959933 · one of two readings recorded this
HOMA-IR
decreases, p = 0.068
There was a tendency for decreased HOMA-IR index (p = 0.068; Mann–Whitney U test)
PMID 30959933 · one of two readings recorded this
body weight gain, EchoMRI total body fat mass, WAT depot weights, inguinal adipocyte size and WAT gene expression in HFD-fed C57BL/6J mice given ethanolic Phaeodactylum tricornutum extract (PTE) 100 or 300 mg/kg/day
decreases
Not recorded as a finding: the intervention held more than the compound
The PTE300 group also revealed less total body fat mass than controls in body composition analyses performed after 5, 14, and 22 days on the HFD.
PMID 30959933 · one of two readings recorded this
body weight gain, total body fat mass by EchoMRI, epididymal and inguinal WAT mass in HFD-fed C57BL/6J mice
decreases, PTE300 mice gained less body weight than controls, statistically significant for PTE300
Not recorded as a finding: the intervention held more than the compound
The PTE-treated mice gained less body weight than controls upon HFD feeding, an effect that reached statistical significance for PTE300.
PMID 30959933 · one of two readings recorded this
body weight gain
decreases
control, PTE100, and PTE300 mice had gained 7.0 ± 0.5, 6.0 ± 1.0, and 4.5 ± 0.5 g
PMID 30959933 · one of two readings recorded this
body weight lost upon 6 h fast
increases
Body weight lost upon a 6 h fast, used as an indicator of energy expenditure, was maximal in the PTE300 group
PMID 30959933 · one of two readings recorded this
Cd36 mRNA expression in 3T3-L1 adipocytes
increases
Cd36 mRNA levels were induced following exposure to PTE, but not fucoxanthin
PMID 30959933 · one of two readings recorded this
Cd36 mRNA expression in BAT
increases, p = 0.046
increased gene expression in BAT of Cd36 (p = 0.046; Kruskal–Wallis test)
PMID 30959933 · one of two readings recorded this
Cd36 mRNA expression
decreases, p = 0.078
there were trends to down-regulation for the lipogenesis-related gene Srebf1 and the fatty acid uptake-related gene Cd36 as well (p = 0.099 and p = 0.078, respectively; Kruskal–Wallis test)
PMID 30959933 · one of two readings recorded this
Cpt1 mRNA expression
increases, p = 0.085
Cpt1 was 4 times and Ucp1 at least 11 times upregulated in inguinal WAT of PTE-supplemented mice, indicating an increased capacity for fatty acid oxidation and thermogenesis (p = 0.085 and p = 0.022, respectively; Kruskal–Wallis test)
PMID 30959933 · one of two readings recorded this
Cpt1a mRNA expression in 3T3-L1 adipocytes
increases
Cpt1a mRNA levels were strongly, relative to levels in control cells, similarly induced by both PTE and fucoxanthin exposure
PMID 30959933 · one of two readings recorded this
crown-like structures in inguinal WAT
increases
an even more consistent occurrence of CLS was found in the PTE300-supplemented group, for which CLSs were detected in all five animals examined
PMID 30959933 · one of two readings recorded this
energy intake
no effect
Differences in body weight gain were not because of the differences in energy intake, which was similar in the three experimental groups throughout the entire duration of the HFD challenge
PMID 30959933 · one of two readings recorded this
epididymal depot weight as percentage of body weight (adiposity index)
decreases
The weight of the epididymal depot expressed as percentage of body weight, which is commonly used as an adiposity index in mice, was significantly lower in the PTE300 group compared to the control group
PMID 30959933 · one of two readings recorded this
epididymal WAT mass
decreases
the mass of the epididymal and inguinal WAT depots was significantly lower (by 24% and 17%, respectively) in the PTE300 group compared with the control group
PMID 30959933 · one of two readings recorded this
Fasn mRNA expression in 3T3-L1 adipocytes
decreases
Fasn mRNA levels were decreased following exposure to fucoxanthin, but not PTE
PMID 30959933 · one of two readings recorded this
Fasn mRNA expression in BAT
decreases, p = 0.049
mRNA levels of the lipogenic genes Fasn and Srebf1 were also down-regulated in BAT of PTE-supplemented mice (p = 0.049 and p = 0.074, respectively; Kruskal–Wallis test)
PMID 30959933 · one of two readings recorded this
fed blood glucose
no effect
Fed blood glucose levels at the end of the experiment did not significantly differ between groups (control, 180 ± 8.1; PTE100, 186 ± 9.8; PTE300, 191 ± 10.7 mg/dL)
PMID 30959933 · one of two readings recorded this
final body weight
decreases
final body weights were 35.1 ± 0.6, 33.5 ± 1.4, and 33 ± 0.7 g
PMID 30959933 · one of two readings recorded this
inguinal WAT adipocyte size distribution
decreases, p = 0.001
The Kolmogorov–Smirnov test indicated that the difference in distributions of cell size between control and PTE-supplemented mice was statistically significant (p < 0.001 for both PTE doses)
PMID 30959933 · one of two readings recorded this
inguinal WAT mass
decreases
the mass of the epididymal and inguinal WAT depots was significantly lower (by 24% and 17%, respectively) in the PTE300 group compared with the control group
PMID 30959933 · one of two readings recorded this
initial body weight
no effect
The average initial body weight was 27.7 ± 0.5 g and did not differ significantly among the three experimental groups
PMID 30959933 · one of two readings recorded this
Lipe mRNA expression in BAT
decreases, p = 0.029
downregulated expression in BAT of the lipolytic genes Lipe and Pnpla2 (p = 0.029 and p = 0.057, respectively; Kruskal–Wallis test)
PMID 30959933 · one of two readings recorded this
Lipe mRNA expression
decreases, p = 0.039
mRNA levels of lipolysis-related genes Lipe, encoding hormone sensitive lipase, and Plin1, encoding perilipin 1, were significantly down-regulated (p = 0.039 and p = 0.033, respectively; Kruskal–Wallis test)
PMID 30959933 · one of two readings recorded this
lipid metabolism gene expression (same genes as epididymal)
no effect
In subcutaneous (inguinal) WAT, expression of these same genes was unaffected by PTE supplementation
PMID 30959933 · one of two readings recorded this
liver histology (hepatosteatosis)
no effect
Histological analysis of the liver was largely normal and did not reveal obvious hepatosteatosis in any of the experimental groups
PMID 30959933 · one of two readings recorded this
Lpl mRNA expression
decreases
mRNA levels in the epididymal fat depot of Lpl, coding for lipoprotein lipase that enables utilization of fatty acids from circulating triacylglycerols, were significantly down-regulated in the PTE300 mice relative to controls
PMID 30959933 · one of two readings recorded this
Mest mRNA expression
decreases
mRNA expression levels of mesoderm-specific transcript homolog protein (Mest), used as a marker of WAT expansion, were markedly decreased in inguinal WAT of PTE-supplemented mice
PMID 30959933 · one of two readings recorded this
Plin1 mRNA expression
decreases, p = 0.033
mRNA levels of lipolysis-related genes Lipe, encoding hormone sensitive lipase, and Plin1, encoding perilipin 1, were significantly down-regulated (p = 0.039 and p = 0.033, respectively; Kruskal–Wallis test)
PMID 30959933 · one of two readings recorded this
Pnpla2 mRNA expression in BAT
decreases, p = 0.057
downregulated expression in BAT of the lipolytic genes Lipe and Pnpla2 (p = 0.029 and p = 0.057, respectively; Kruskal–Wallis test)
PMID 30959933 · one of two readings recorded this
R-QUICKI
increases, p = 0.1
increased R-QUICKI index (p = 0.100; Mann–Whitney U test) in the PTE100-supplemented group
PMID 30959933 · one of two readings recorded this
retroperitoneal WAT mass and BAT mass
no effect
There were no differences between groups in retroperitoneal WAT mass and BAT mass
PMID 30959933 · one of two readings recorded this
Srebf1 mRNA expression in BAT
decreases, p = 0.074
mRNA levels of the lipogenic genes Fasn and Srebf1 were also down-regulated in BAT of PTE-supplemented mice (p = 0.049 and p = 0.074, respectively; Kruskal–Wallis test)
PMID 30959933 · one of two readings recorded this
Srebf1 mRNA expression
decreases, p = 0.099
there were trends to down-regulation for the lipogenesis-related gene Srebf1 and the fatty acid uptake-related gene Cd36 as well (p = 0.099 and p = 0.078, respectively; Kruskal–Wallis test)
PMID 30959933 · one of two readings recorded this
total body fat mass
decreases
The PTE300 group also revealed less total body fat mass than controls in body composition analyses performed after 5, 14, and 22 days on the HFD
PMID 30959933 · one of two readings recorded this
total liver lipid content
decreases
Biochemical analysis showed a tendency for lower total liver lipid content in the PTE-supplemented mice
PMID 30959933 · one of two readings recorded this
Ucp1 and Cpt1 mRNA expression in BAT
no effect
PTE supplementation had no effect on the expression of Ucp1 or Cpt1 at the mRNA level
PMID 30959933 · one of two readings recorded this
UCP1 and MFN2 protein in BAT
increases
showing dose-dependent increased levels of both proteins in BAT of PTE-supplemented animals as compared to controls
PMID 30959933 · one of two readings recorded this
Ucp1 mRNA detection in 3T3-L1 adipocytes
no effect
Ucp1 mRNA could not be detected in mature 3T3-L1 adipocytes irrespective of treatment
PMID 30959933 · one of two readings recorded this
Ucp1 mRNA expression
increases, p = 0.022
Cpt1 was 4 times and Ucp1 at least 11 times upregulated in inguinal WAT of PTE-supplemented mice, indicating an increased capacity for fatty acid oxidation and thermogenesis (p = 0.085 and p = 0.022, respectively; Kruskal–Wallis test)
PMID 30959933 · one of two readings recorded this
UCP1 protein in inguinal WAT
increases
UCP1 could not be detected in inguinal WAT in any control mice, but it was detected by immunoblotting in one-sixth PTE100 and two-fifths PTE300 mice analyzed (results not shown)
PMID 30959933 · one of two readings recorded this
3T3-L1 cell cytotoxicity of FX
no effect
We indicated that FX was not toxic to cells below 80 μM, and PE showed cytotoxicity at 1000 μg/mL (Figure S2)
PMID 31137922 · one of two readings recorded this
3T3-L1 cell cytotoxicity of PE
decreases
We indicated that FX was not toxic to cells below 80 μM, and PE showed cytotoxicity at 1000 μg/mL (Figure S2)
PMID 31137922 · one of two readings recorded this
abdominal fat volume (micro CT)
decreases
For abdominal fat, the values in the PE-treated groups were 43.34~57.96% of that in the HFD
PMID 31137922 · one of two readings recorded this
body weight AUC
decreases
Mice in the HFD plus PE treatment group showed a lower AUC level than the HFD group, while mice in the PE plus conjugated linoleic acid (CLA) group showed the lowest AUC level
PMID 31137922 · one of two readings recorded this
body weight AUC
increases, p = 0.001
After 6 weeks, the area under the curve (AUC) of body weights was higher in the HFD group than in the normal diet (ND) group and other groups (p < 0.001)
PMID 31137922 · one of two readings recorded this
body weight gain
decreases
all PE-treated groups showed weight loss in a dose-dependent manner compared to the HFD group, with greater effects than in the positive control (FX)
PMID 31137922 · one of two readings recorded this
C/EBPα expression in adipose tissue
decreases
In addition, C/EBPα expression levels were lower in the PE-treated groups
PMID 31137922 · one of two readings recorded this
C/EBPα protein level in 3T3-L1 cells
no effect
However, neither FX nor PE affected the level of C/EBPα
PMID 31137922 · one of two readings recorded this
inguinal adipose tissue weight
increases
Inguinal adipose tissue weight was significantly higher in the HFD group than the ND group on both the right and left
PMID 31137922 · one of two readings recorded this
inguinal adipose tissue weight
decreases
the PE-treated groups exhibited lower values than the HFD group in inguinal adipose tissue weight over 40% (p < 0.01 or p < 0.05)
PMID 31137922 · one of two readings recorded this
initial body weight
no effect
Before treatment, the average initial body weight of the mice was 24.38 g, with no significant differences among the 7 groups
PMID 31137922 · one of two readings recorded this
intracellular lipid accumulation (Oil Red O) in 3T3-L1 cells
decreases
FX at 40 μM inhibited lipid accumulation by 30% compared to the control during differentiation
PMID 31137922 · one of two readings recorded this
intracellular lipid accumulation (Oil Red O) in 3T3-L1 cells
decreases
PE decreased lipid accumulation at 250 μg/mL during adipocyte differentiation
PMID 31137922 · one of two readings recorded this
liver fat globule size (Oil Red O)
decreases, p = 0.001
the PE-M + CLA group showed the biggest reduction in fat globule size (72.5% of that in the HFD group, p < 0.001)
PMID 31137922 · one of two readings recorded this
liver fat globule size (Oil Red O)
decreases
After treatment with FX or PE, the lipid droplet numbers decreased and the fat globule sizes reduced strongly to 75.66% of that in the HFD group in a dose-dependent manner
PMID 31137922 · one of two readings recorded this
liver triglyceride level
decreases
In Figure 3C, the level of liver in TG in the PE-treated group reduced significantly and dose-dependently
PMID 31137922 · one of two readings recorded this
liver weight
decreases
PE treatment groups (PE-L, PE-M, PE-H) and the PE-M plus CLA group showed significantly lower weight values (1.12%~7.45% at p < 0.001 or p < 0.01) than in the HFD group
PMID 31137922 · one of two readings recorded this
PPARγ expression in adipose tissue
decreases
PPARγ expression levels were significantly lower in the PE-L, PE-M, PE-H, and PE-M + CLA groups than in the HFD group by 0.62-, 0.54-, 0.51-, and 0.45- fold, respectively
PMID 31137922 · one of two readings recorded this
PPARγ expression in adipose tissue
decreases
PPARγ expression levels were significantly lower in the PE-L, PE-M, PE-H, and PE-M + CLA groups than in the HFD group by 0.62-, 0.54-, 0.51-, and 0.45- fold, respectively
PMID 31137922 · one of two readings recorded this
PPARγ expression in adipose tissue
decreases
PPARγ expression levels were significantly lower in the PE-L, PE-M, PE-H, and PE-M + CLA groups than in the HFD group by 0.62-, 0.54-, 0.51-, and 0.45- fold, respectively
PMID 31137922 · one of two readings recorded this
PPARγ expression in adipose tissue
decreases
PPARγ expression levels were significantly lower in the PE-L, PE-M, PE-H, and PE-M + CLA groups than in the HFD group by 0.62-, 0.54-, 0.51-, and 0.45- fold, respectively
PMID 31137922 · one of two readings recorded this
PPARγ protein level in 3T3-L1 cells
decreases
At high levels, FX and PE clearly decreased PPARγ levels and dose-dependently increased the UCP1 level
PMID 31137922 · one of two readings recorded this
serum ALT
decreases
FX and PE-M + CLA treatment significantly decreased ALT levels, whereas PE treatment slightly decreased ALT levels, compared with those in the HFD group
PMID 31137922 · one of two readings recorded this
serum aspartate aminotransferase (AST) in HFD-fed mice
no effect, slight decrease, difference not statistically significant
Not recorded as a finding: paper states the AST decrease was not statistically significant, with a direction word 'slight decrease' and no estimate; not recorded as a claim
The FX, PE, and PE-M + CLA groups showed a slight decrease in AST levels compared with the HFD group, although the difference was not statistically significant.
PMID 31137922 · one of two readings recorded this
serum AST
no effect
The FX, PE, and PE-M + CLA groups showed a slight decrease in AST levels compared with the HFD group, although the difference was not statistically significant
PMID 31137922 · one of two readings recorded this
serum LDL cholesterol, HITACHI 7180 chemistry analyser, HFD mice given FX 0.1 mg/kg/day
no effect
Not recorded as a finding: object span 'LDL' is not an accepted span for the LDL cholesterol node; sentence is otherwise usable
FX treatment did not affect the levels of LDL, which is generally considered as a pathological marker.
PMID 31137922 · one of two readings recorded this
serum LDL
no effect
FX treatment did not affect the levels of LDL, which is generally considered as a pathological marker
PMID 31137922 · one of two readings recorded this
serum LDL
decreases
PE administration decreased the LDL levels in a dose-dependent manner, especially PE-H, which significantly decreased the LDL levels
PMID 31137922 · one of two readings recorded this
serum TC and HDL
no effect
Neither FX nor PE affected the HFD-induced increase in TC and high-density lipoprotein (HDL) levels
PMID 31137922 · one of two readings recorded this
serum TC and LDL
increases
the HFD group showed a slight increase in the level of triacylglyceride (TG) and a significant increase in total cholesterol (TC) and low-density lipoprotein (LDL) compare with the ND group
PMID 31137922 · one of two readings recorded this
serum total cholesterol and HDL in HFD mice given FX or Phaeodactylum extract
no effect
Not recorded as a finding: sentence pools FX with the extract (PE) and HDL span is not an accepted span for the HDL node
Neither FX nor PE affected the HFD-induced increase in TC and high-density lipoprotein (HDL) levels.
PMID 31137922 · one of two readings recorded this
serum triacylglyceride (TG)
decreases
Administration of PE-M and PE-M + CLA for 6 weeks significantly decreased the TG level compared with that in the HFD group
PMID 31137922 · one of two readings recorded this
subcutaneous fat volume (micro CT)
decreases
for subcutaneous fat, the values in the PE-treated groups were 67.68~76.78% of that of the HFD group
PMID 31137922 · one of two readings recorded this
total fat volume (micro CT)
decreases
The total fat volumes in the PE-treated groups were 53.30~65.66% of that in the HFD group
PMID 31137922 · one of two readings recorded this
UCP1 expression in adipose tissue
increases
UCP1 expression levels in the PE-M, PE-H, and PE-M + CLA groups were 2.02-, 2.34-, and 2.35-fold higher, respectively
PMID 31137922 · one of two readings recorded this
UCP1 expression in adipose tissue
increases
UCP1 expression levels in the PE-M, PE-H, and PE-M + CLA groups were 2.02-, 2.34-, and 2.35-fold higher, respectively
PMID 31137922 · one of two readings recorded this
UCP1 expression in adipose tissue
increases
UCP1 expression levels in the PE-M, PE-H, and PE-M + CLA groups were 2.02-, 2.34-, and 2.35-fold higher, respectively
PMID 31137922 · one of two readings recorded this
UCP1 protein level in 3T3-L1 cells
increases
At high levels, FX and PE clearly decreased PPARγ levels and dose-dependently increased the UCP1 level
PMID 31137922 · one of two readings recorded this
acetylated FoxO3α
decreases
Fx and Rsv decreased the acetylated FoxO3α induced by HG, respectively
PMID 31842414 · one of two readings recorded this
fibronectin and collagen IV expression, ROS by DCFH-DA, mitochondrial membrane potential in high-glucose rat glomerular mesangial cells
decreases, Fx reduced FN and collagen IV expression induced by HG
Not recorded as a finding: no outcome node for in vitro extracellular matrix protein expression or cellular ROS
Here, we found that Fx can effectively reduce the expression of FN and collagen IV induced by HG in GMCs, suggesting that Fx can alleviate the accumulation of ECM in DN.
PMID 31842414 · both readings recorded this
fibronectin (FN) and collagen IV expression
decreases
we found that Fx can effectively reduce the expression of FN and collagen IV induced by HG in GMCs
PMID 31842414 · one of two readings recorded this
FoxO3α expression after Sirt1 inhibitor EX527 or Akt activator SC79
no effect
Fx restored the expression of FoxO3α inhibited by HG but could not restore the expression of FoxO3α in GMCs pretreated with EX527 and SC79, respectively
PMID 31842414 · one of two readings recorded this
FoxO3α expression and phosphorylated FoxO3α (S253) with HG over time
decreases
The results showed that the expression of FoxO3α was the lowest at 12 h of HG treatment, while phosphorylated FoxO3α (S253) was the highest at this time point
PMID 31842414 · one of two readings recorded this
FoxO3α expression and phosphorylated FoxO3α
increases
It is gratifying to see that Fx can successfully reverse the decrease expression of FoxO3α and the increase of phosphorylated FoxO3α induced by HG
PMID 31842414 · one of two readings recorded this
mitochondrial membrane potential
increases
The results showed that the membrane potential decreased significantly in the HG group, which was counteracted by Fx
PMID 31842414 · one of two readings recorded this
MnSOD expression
increases
Fx was more effective than both in promoting the expression of MnSOD in the HG condition
PMID 31842414 · one of two readings recorded this
nuclear FoxO3α after Akt activator SC79
decreases
Akt inhibitor MK2206 significantly increased the FoxO3α in the nucleus, while Akt activator SC79 abolished concentration of FoxO3α in the nucleus induced by Fx
PMID 31842414 · one of two readings recorded this
nuclear FoxO3α after Sirt1 inhibitor EX527
decreases
the addition of Sirt1 inhibitor EX527 abolished Fx-induced FoxO3α nuclear transportation
PMID 31842414 · one of two readings recorded this
nuclear FoxO3α
increases
The results showed that HG treatment decreased the FoxO3α in the nucleus; however, increased FoxO3α was observed in the nucleus after Fx treatment
PMID 31842414 · one of two readings recorded this
p-Akt activation
decreases
Fx and MK2206, a specific inhibitor of Akt, successfully reversed the activation of Akt induced by HG
PMID 31842414 · one of two readings recorded this
ROS production
decreases
Fx effectively inhibited the overproduction of ROS induced by HG in an Akt/Sirt1/FoxO3α-dependent manner
PMID 31842414 · one of two readings recorded this
Sirt1 protein level
increases
The Sirt1 activator Rsv effectively promoted the protein level of Sirt1 under HG, and Fx produced similar pharmacological effects to Rsv
PMID 31842414 · one of two readings recorded this
AD pathology improvement
decreases
0.1% FX significantly improved AD pathology with better reproducibility than 0.1% TAC
PMID 32235696 · one of two readings recorded this
BMMC degranulation
decreases
After differentiation for three weeks, FX showed concentration-dependent inhibitory effects on degranulation of BMMCs (Figure S1C)
PMID 32235696 · one of two readings recorded this
eosinophil infiltration
decreases
eosinophils with deeply stained granules were often found only in Vas treated skin
PMID 32235696 · one of two readings recorded this
epidermal thickening
no effect
Pathological analysis revealed no epidermal thickening after five weeks of continuous application of each compound
PMID 32235696 · one of two readings recorded this
FcεRIα expression
decreases
FX or TAC significantly inhibited FcεRlα
PMID 32235696 · one of two readings recorded this
GATA1 and GATA2 expression
modulates
qRT-PCR analysis showed that GATA1 and GATA2 were regulated by FX or TAC in vivo
PMID 32235696 · one of two readings recorded this
Il-10+TGF-β+Sca1+ ILCreg in dermis
increases
Il-10+TGF-β+Sca1+ ILCreg were dominantly observed in FX treated groups in dermis compared to Vas or TAC treated groups
PMID 32235696 · one of two readings recorded this
Il-17 expression
decreases
Il-17 expression levels were significantly suppressed by TAC
PMID 32235696 · one of two readings recorded this
Il-2 and Il-10 expression
increases
FX but not TAC dramatically stimulated Il-2 and Il-10 expression levels in Nc/Nga mice
PMID 32235696 · one of two readings recorded this
Il-33 expression
decreases
Il-33 expression levels were downregulated in FX or TAC treated skin to a similar extent
PMID 32235696 · one of two readings recorded this
Il-5 and Il-13 expression
increases
FX significantly enhanced the expression of Il-5 and Il-13
PMID 32235696 · one of two readings recorded this
inflammatory cytokine expression, NF-κB activity and viability in HaCaT cells
no effect
FX or TAC did not influence inflammatory cytokine expression levels (Figure S2A,B), NF-κB activities (Figure S2C), or cell viabilities in human keratinocytes HaCaT cells (Figure S3)
PMID 32235696 · one of two readings recorded this
lymphocyte proliferation
no effect
There was no effect on lymphocytes proliferation (Figure S1B)
PMID 32235696 · one of two readings recorded this
modified clinical skin severity score (itch, erythema/hemorrhage, edema, excoriation/erosion, scaling/dryness, each graded 0-3) and scratching behaviour in NC/Nga mice given 0.1% fucoxanthin in Vaseline topically, versus Vaseline and 0.1% tacrolimus; serum IgE; mast cell and eosinophil counts; skin cytokine expression by qRT-PCR
decreases
Not recorded as a finding: this platform holds no node for the endpoint
FX significantly reduced the modified clinical skin severity score from day 22 after the start of application.
PMID 32235696 · one of two readings recorded this
modified clinical skin severity score
decreases
FX significantly reduced the modified clinical skin severity score from day 22 after the start of application
PMID 32235696 · one of two readings recorded this
scratching behavior (itch) and modified clinical skin severity score in NC/Nga mice with atopic dermatitis, topical 0.1% FX vs Vaseline vs 0.1% tacrolimus
decreases, FX significantly reduced the modified clinical skin severity score from day 22
Not recorded as a finding: this platform holds no node for the endpoint
FX significantly reduced the modified clinical skin severity score from day 22 after the start of application.
PMID 32235696 · one of two readings recorded this
scratching behavior (itch)
decreases
Until day 15, the scratching behavior was reduced by FX or TAC, but increased again on day 35
PMID 32235696 · one of two readings recorded this
scratching behavior (itch)
increases
Until day 15, the scratching behavior was reduced by FX or TAC, but increased again on day 35
PMID 32235696 · one of two readings recorded this
scratching behavior (itch)
decreases
Although the improvement effect was also recognized by TAC ointment, the improvement effect of FX was significant
PMID 32235696 · one of two readings recorded this
serum IgE
no effect
elevated serum IgE values in Vas-, FX-, or TAC-treated mice were not changed, respectively
PMID 32235696 · one of two readings recorded this
TGF-β expression
increases
TGF-β expression levels were dramatically upregulated by each compound
PMID 32235696 · one of two readings recorded this
toluidine blue-positive mast cell number
decreases
the number of toluidine blue (TB)-positive mast cells was significantly reduced as compared with the Vas treated group
PMID 32235696 · one of two readings recorded this
trans-epidermal water loss (TEWL)
unclear
From the follow-up analysis of trans-epidermal water loss (TEWL) values over time, transcutaneous water evaporation above 40 g/m2·hour was recorded in all mice
PMID 32235696 · one of two readings recorded this
TSLP expression
no effect
Thymic stromal lymphopoietin (TSLP) expression levels were not influenced by FX or TAC, while TSLP receptor (TSLPR) expression levels were downregulated by FX or TAC to a similar extent
PMID 32235696 · one of two readings recorded this
TSLP receptor (TSLPR) expression
decreases
Thymic stromal lymphopoietin (TSLP) expression levels were not influenced by FX or TAC, while TSLP receptor (TSLPR) expression levels were downregulated by FX or TAC to a similar extent
PMID 32235696 · one of two readings recorded this
Expression of MMP-1, MMP-2 and MMP-9
decreases
it significantly decreased the expression of matrix metalloproteinase (MMP)-1, MMP-2, and MMP-9 at 25 µg/ml
PMID 32271708 · one of two readings recorded this
Fibroblast proliferation
no effect
The concentrate (up to 25 µg/ml) did not affect the proliferation of human fibroblasts
PMID 32271708 · one of two readings recorded this
Procollagen synthesis
increases
the concentrate significantly increased procollagen synthesis in the fibroblasts at 12.5 and 25 µg/ml
PMID 32271708 · one of two readings recorded this
Skin moisture and elasticity
increases
skin moisture and elasticity increased significantly from week 4
PMID 32271708 · one of two readings recorded this
Wrinkles around the eyes
decreases
Evaluation of wrinkles around the eyes using the replica method showed a statistically significant decrease in wrinkles at week 8
PMID 32271708 · one of two readings recorded this
bioaccessibility and physicochemical stability of fucoxanthin achieved via nano/micro-encapsulation delivery systems for oral food/nutraceutical use, no clinical or physiological outcome measured
increases, these formulated nano/micro-capsules have proven to be effective in stabilizing and enhancing the bioaccessibility of fucoxanthin, no quantitative figure given
Not recorded as a finding: this platform holds no node for the endpoint
These formulated nano/micro-capsules have proven to be effective in stabilizing and enhancing the bioaccessibility of fucoxanthin.
PMID 33151231 · one of two readings recorded this
bioaccessibility and physicochemical stability of fucoxanthin after encapsulation
increases
These formulated nano/micro-capsules have proven to be effective in stabilizing and enhancing the bioaccessibility of fucoxanthin.
PMID 33151231 · one of two readings recorded this
bioaccessibility and stability of fucoxanthin encapsulated in nano/micro-delivery systems
increases
These formulated nano/micro-capsules have proven to be effective in stabilizing and enhancing the bioaccessibility of fucoxanthin.
PMID 33151231 · one of two readings recorded this
BALF protein concentration
decreases
the protein concentration of BALF was significantly increased after LPS stimulation, whereas the pre-treatment of Fucoxanthin could reverse this increase
PMID 33323555 · one of two readings recorded this
BALF total protein concentration by BCA assay, BALF cell number, and lung wet/dry weight ratio in LPS-induced acute lung injury in mice; COX-2 and iNOS expression in RAW264.7 cells
decreases, pre-treatment with Fucoxanthin effectively decreased the lung wet/dry ratio
Not recorded as a finding: this platform holds no node for the endpoint
Nevertheless, pre-treatment with Fucoxanthin effectively decreased the lung wet/dry ratio.
PMID 33323555 · one of two readings recorded this
cell number in BALF
decreases
The LPS stimulation led to a significant increase in the number of cells in the BALF, which was decreased by pre-treatment with Fucoxanthin
PMID 33323555 · one of two readings recorded this
COX-2 and iNOS expression in lung tissue
decreases
Fucoxanthin significantly attenuated LPS-induced lung inflammation, as evidenced by COX-2 and iNOS expression in lung tissue
PMID 33323555 · one of two readings recorded this
COX-2 and iNOS protein expression in LPS-stimulated RAW264.7 cells
decreases
Western blot analysis also showed that Fucoxanthin could dramatically reduce the protein expression of COX-2 and iNOS induced by LPS
PMID 33323555 · one of two readings recorded this
lung histopathology (alveolar wall thickness, hemorrhage, collapse, infiltration)
decreases
As a comparison, the group pretreated with Fucoxanthin displayed very little histopathological changes
PMID 33323555 · one of two readings recorded this
lung macrophage infiltration (CD68)
decreases
Pre-treatment with Fucoxanthin significantly attenuated LPS-induced lung macrophage infiltration into the lung
PMID 33323555 · one of two readings recorded this
lung wet/dry weight ratio, BALF total protein (BCA) and BALF cell count in LPS-induced acute lung injury in mice given fucoxanthin 10 mg/kg i.v.; COX-2, iNOS, IL-6, TNF-α expression in LPS-stimulated RAW264.7 cells
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Nevertheless, pre-treatment with Fucoxanthin effectively decreased the lung wet/dry ratio.
PMID 33323555 · one of two readings recorded this
lung wet/dry weight ratio
decreases
Nevertheless, pre-treatment with Fucoxanthin effectively decreased the lung wet/dry ratio
PMID 33323555 · one of two readings recorded this
mRNA expression of COX-2, iNOS, IL-10, IL-6, TNF-α, IL-1β in LPS-stimulated RAW264.7 cells
decreases
pre-treatment with Fucoxanthin completely diminished the stimulatory effects of LPS in a dose-dependent manner
PMID 33323555 · one of two readings recorded this
NLRP3 signal pathway
no effect
The results showed that Fucoxanthin did not affect the NLRP3 signal pathway
PMID 33323555 · one of two readings recorded this
nuclear translocation of NF-κB
decreases
As shown in Figure 4A, Fucoxanthin effectively blocked the nuclear translocation of NF-κB
PMID 33323555 · one of two readings recorded this
p-NF-κB (p-p65) expression
decreases
The results showed that Fucoxanthin only affected the expression level of p-NF-κB (p-p65), but not the expression level of total NF-κB (p65)
PMID 33323555 · one of two readings recorded this
RAW264.7 cell viability (CCK-8)
no effect
As shown in Figure 1B, RAW264.7 cells were treated with 0-20 μM Fucoxanthin for 24 hours had no cytotoxic effect, whereas cell viability was significantly reduced at the concentration of 40 μM
PMID 33323555 · one of two readings recorded this
RAW264.7 cell viability (CCK-8)
decreases
As shown in Figure 1B, RAW264.7 cells were treated with 0-20 μM Fucoxanthin for 24 hours had no cytotoxic effect, whereas cell viability was significantly reduced at the concentration of 40 μM
PMID 33323555 · one of two readings recorded this
TLR4/MyD88 signaling in LPS-stimulated RAW264.7 cells
decreases
As we expected, Fucoxanthin effectively suppressed the TLR4/MyD88 signaling pathway
PMID 33323555 · one of two readings recorded this
total NF-κB (p65) expression
no effect
The results showed that Fucoxanthin only affected the expression level of p-NF-κB (p-p65), but not the expression level of total NF-κB (p65)
PMID 33323555 · one of two readings recorded this
cytosolic Nrf2 expression
decreases
Expression of nuclear Nrf2 significantly increased, while cytosolic Nrf2 expression dose-dependently decreased
PMID 33673704 · one of two readings recorded this
DC-STAMP mRNA expression
decreases
DC-STAMP mRNA expression was significantly decreased upon treatment with FX in a dose-dependent manner
PMID 33673704 · one of two readings recorded this
ERK and p38 phosphorylation
decreases
The treatment of RAW264.7 cells with FX significantly reduced the phosphorylation of ERK and p38 in a concentration-dependent manner
PMID 33673704 · one of two readings recorded this
JNK, NF-κB and PI3K phosphorylation
no effect
However, JNK, NF-κB, and PI3K phosphorylation was not altered following FX treatment
PMID 33673704 · one of two readings recorded this
MMP-9 level in culture supernatant
decreases
cells treated with 5 μM FX showed a significant decrease in MMP-9 levels
PMID 33673704 · one of two readings recorded this
NFATc1 expression
decreases
The expression of NFATc1 in sRANKL- or TNF/IL-6-stimulated RAW264.7 cells decreased upon treatment with FX in a dose-dependent manner
PMID 33673704 · one of two readings recorded this
nuclear Nrf2 expression
increases
Expression of nuclear Nrf2 significantly increased, while cytosolic Nrf2 expression dose-dependently decreased
PMID 33673704 · one of two readings recorded this
osteoclast differentiation of human CD14+ monocytes
decreases
In experiments using human CD14+ monocytes, 0 to 5 μM of FX dose-dependently suppressed RANKL- and TNF-α/IL-6-induced osteoclast differentiation from osteoclast precursors
PMID 33673704 · one of two readings recorded this
procaspase-3 and PARP cleavage
no effect
no cleavage of procaspase-3 and poly ADP ribose polymerase (PARP; Figure 1B) was detected in cells treated with ≤10 μM FX
PMID 33673704 · one of two readings recorded this
proportion of phospho-Nrf2 in nucleus versus cytoplasm
increases
The proportions of phospho-Nrf2 expression in the nucleus compared to in the cytoplasm were significantly augmented by FX
PMID 33673704 · one of two readings recorded this
RAW264.7 cell viability
decreases
However, the number of viable cells after treatment with 10 μM of FX was significantly lower than the number of untreated cells was
PMID 33673704 · one of two readings recorded this
RAW264.7 cell viability
no effect
FX did not affect cell viability at a concentration of ≤5 μM
PMID 33673704 · one of two readings recorded this
resorption pit area
decreases
the resorption pit area was significantly decreased upon treatment with FX in a dose-dependent manner
PMID 33673704 · one of two readings recorded this
total Nrf2 level in cell lysates
no effect
Nrf2 levels in total cell lysates were not affected by FX treatment
PMID 33673704 · one of two readings recorded this
TRAP-positive multinucleated cells (RAW264.7)
decreases
Under these conditions, FX treatment decreased the number of TRAP-positive multinucleated cells in a dose-dependent manner
PMID 33673704 · one of two readings recorded this
TRAP-positive multinucleated osteoclast count and resorption pit area in RAW264.7 cells; MMP-9 by ELISA
decreases, dose-dependent decrease
Not recorded as a finding: no outcome node for osteoclast differentiation or resorption pit area in cell culture
As shown in Figure 3, the resorption pit area was significantly decreased upon treatment with FX in a dose-dependent manner.
PMID 33673704 · one of two readings recorded this
ARE-luciferase activity with FUC pretreatment
increases, p = 0.05
FUC pretreatment significantly increased the activity of ARE-luciferase in 6-OHDA-induced PC12 cells compared with the 6-OHDA treatment group (P < 0.05)
PMID 33777321 · one of two readings recorded this